High Drug Resistance in Feline Mammary Carcinoma Cell Line (FMCm) and Comparison with Human Breast Cancer Cell Line (MCF-7)

Overview

Journal Animals (Basel)

Date 2021 Aug 27

PMID 34438778

Citations 1

Authors

Ana Salome Correia

Rita Matos

Fatima Gartner

Irina Amorim

Nuno Vale

Affiliations

Soon will be listed here.

Abstract

Drug repurposing and drug combination are important therapeutic approaches in cancer therapy. Drug repurposing aims to give new indications to drugs, rather than the original indication, whereas drug combination presupposes that the effect that is obtained should be more beneficial than the effect obtained by the individual drugs. Previously, drug repurposing and the combination of different drugs was evaluated in our research group against human breast cancer cells (MCF-7 cells). Our results demonstrated that the response obtained through the combination of drugs, when compared with the single drugs, led to more synergic responses. Therefore, using potential drugs for repurposing, combined with a reference drug in breast cancer (5-Fluorouracil), was the major aim of this project, but for the first time using the feline mammary carcinoma cell line, FMCm. Surprisingly, the feline neoplastic cells demonstrated considerable resistance to the drugs tested in isolation, and the combination was not effective, which contrasted with the obtained MCF-7 cells' response.

Citing Articles

Contribution of non-steroidal anti-inflammatory drugs to breast cancer treatment: and studies.

Ferreira T, Faustino-Rocha A, Gaspar V, Medeiros R, Mano J, Oliveira P Vet World. 2024; 17(5):1052-1072.

PMID: 38911075 PMC: 11188899. DOI: 10.14202/vetworld.2024.1052-1072.

References

Zhang Y, Cao Y, Sun X, Feng Y, Du Y, Liu F . Chloroquine (CQ) exerts anti-breast cancer through modulating microenvironment and inducing apoptosis. Int Immunopharmacol. 2016; 42:100-107. DOI: 10.1016/j.intimp.2016.11.027. View

Silva S, Alves C, Duarte D, Costa A, Sarmento B, Almeida A . Model Amphipathic Peptide Coupled with Tacrine to Improve Its Antiproliferative Activity. Int J Mol Sci. 2021; 22(1). PMC: 7795729. DOI: 10.3390/ijms22010242. View

Uyama R, Hong S, Nakagawa T, Yazawa M, Kadosawa T, Mochizuki M . Establishment and characterization of eight feline mammary adenocarcinoma cell lines. J Vet Med Sci. 2006; 67(12):1273-6. DOI: 10.1292/jvms.67.1273. View

Wohlhueter R, McIvor R, Plagemann P . Facilitated transport of uracil and 5-fluorouracil, and permeation of orotic acid into cultured mammalian cells. J Cell Physiol. 1980; 104(3):309-19. DOI: 10.1002/jcp.1041040305. View

Zappulli V, Zan G, Cardazzo B, Bargelloni L, Castagnaro M . Feline mammary tumours in comparative oncology. J Dairy Res. 2005; 72 Spec No:98-106. DOI: 10.1017/s0022029905001263. View

Correia A, Silva D, Correia A, Vilanova M, Gartner F, Vale N . Study of New Therapeutic Strategies to Combat Breast Cancer Using Drug Combinations. Biomolecules. 2018; 8(4). PMC: 6315516. DOI: 10.3390/biom8040175. View

Vieira A, Paredes J . P-cadherin and the journey to cancer metastasis. Mol Cancer. 2015; 14:178. PMC: 4595126. DOI: 10.1186/s12943-015-0448-4. View

Valdes-Abadia B, Moran-Zendejas R, Rangel-Flores J, Rodriguez-Menchaca A . Chloroquine inhibits tumor-related Kv10.1 channel and decreases migration of MDA-MB-231 breast cancer cells in vitro. Eur J Pharmacol. 2019; 855:262-266. DOI: 10.1016/j.ejphar.2019.05.017. View

Mendonsa A, Na T, Gumbiner B . E-cadherin in contact inhibition and cancer. Oncogene. 2018; 37(35):4769-4780. PMC: 6119098. DOI: 10.1038/s41388-018-0304-2. View

10.

Ribeiro A, Albergaria A, Sousa B, Correia A, Bracke M, Seruca R . Extracellular cleavage and shedding of P-cadherin: a mechanism underlying the invasive behaviour of breast cancer cells. Oncogene. 2009; 29(3):392-402. DOI: 10.1038/onc.2009.338. View

11.

Ishida J, Konishi M, Ebner N, Springer J . Repurposing of approved cardiovascular drugs. J Transl Med. 2016; 14:269. PMC: 5029061. DOI: 10.1186/s12967-016-1031-5. View

12.

Ribeiro A, Sousa B, Carreto L, Mendes N, Nobre A, Ricardo S . P-cadherin functional role is dependent on E-cadherin cellular context: a proof of concept using the breast cancer model. J Pathol. 2012; 229(5):705-18. DOI: 10.1002/path.4143. View

13.

Almeida F, Gameiro A, Correia J, Ferreira F . Histone Deacetylase Inhibitors and Microtubule Inhibitors Induce Apoptosis in Feline Luminal Mammary Carcinoma Cells. Animals (Basel). 2021; 11(2). PMC: 7918990. DOI: 10.3390/ani11020502. View

14.

Foucquier J, Guedj M . Analysis of drug combinations: current methodological landscape. Pharmacol Res Perspect. 2015; 3(3):e00149. PMC: 4492765. DOI: 10.1002/prp2.149. View

15.

Coulson R, Liew S, Connelly A, Yee N, Deb S, Kumar B . The angiotensin receptor blocker, Losartan, inhibits mammary tumor development and progression to invasive carcinoma. Oncotarget. 2017; 8(12):18640-18656. PMC: 5386636. DOI: 10.18632/oncotarget.15553. View

16.

Han K, Jeng E, Hess G, Morgens D, Li A, Bassik M . Synergistic drug combinations for cancer identified in a CRISPR screen for pairwise genetic interactions. Nat Biotechnol. 2017; 35(5):463-474. PMC: 5557292. DOI: 10.1038/nbt.3834. View

17.

Diasio R, Harris B . Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet. 1989; 16(4):215-37. DOI: 10.2165/00003088-198916040-00002. View

18.

Hassan B, Elshafae S, Supsavhad W, Simmons J, Dirksen W, Sokkar S . Feline Mammary Cancer. Vet Pathol. 2016; 54(1):32-43. PMC: 7212821. DOI: 10.1177/0300985816650243. View

19.

Lv Q, Wang D, Yang Z, Yang J, Zhang R, Yang X . Repurposing antitubercular agent isoniazid for treatment of prostate cancer. Biomater Sci. 2018; 7(1):296-306. DOI: 10.1039/c8bm01189c. View

20.

Bertolini F, Sukhatme V, Bouche G . Drug repurposing in oncology--patient and health systems opportunities. Nat Rev Clin Oncol. 2015; 12(12):732-42. DOI: 10.1038/nrclinonc.2015.169. View